Ngai Ho-Yin, Yuen Kar-Kei Steffi, Ng Chi-Man, Cheng Cheung-Hing, Chu Sau-Kwan Peggy
Division of Urology, Department of Surgery, Queen Elizabeth Hospital, Hong Kong, China.
Division of Urology, Department of Surgery, Tuen Mun Hospital, Hong Kong, China.
Asian J Urol. 2017 Jul;4(3):164-173. doi: 10.1016/j.ajur.2017.05.001. Epub 2017 May 25.
Metabolic syndrome (MetS) is a cluster of metabolic abnormalities related to central adiposity and insulin resistance. Its importance is increasingly recognized as it associates with increased risks of metabolic and cardiovascular diseases. These metabolic aberrations of MetS may lead to development of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) in men. A 26.5%-55.6% prevalence of MetS in men with LUTS was reported in worldwide studies. Although the exact biological pathway is not clear yet, insulin resistance, increased visceral adiposity, sex hormone alterations and cellular inflammatory reactions played significant roles in the related pathophysiological processes. Clinician should recognize the cardiovascular and metabolic impacts of MetS in men with LUTS, early risk factors optimization and use of appropriate medical therapy may possibly alter or slower the progression of LUTS/BPH, and potentially avoid unnecessary morbidities and mortalities from cardiovascular and metabolic diseases for those men.
代谢综合征（MetS）是一组与中心性肥胖和胰岛素抵抗相关的代谢异常。随着其与代谢性疾病和心血管疾病风险增加相关联，其重要性日益得到认可。MetS的这些代谢异常可能导致男性良性前列腺增生（BPH）和下尿路症状（LUTS）的发生。全球研究报告显示，LUTS男性中MetS的患病率为26.5% - 55.6%。尽管确切的生物学途径尚不清楚，但胰岛素抵抗、内脏脂肪增多、性激素改变和细胞炎症反应在相关病理生理过程中起重要作用。临床医生应认识到MetS对LUTS男性的心血管和代谢影响，早期优化风险因素并使用适当的药物治疗可能会改变或减缓LUTS/BPH的进展，并有可能避免这些男性因心血管和代谢疾病而出现不必要的发病和死亡。
